Skip to main content
. 2023 Sep 27;24(19):14654. doi: 10.3390/ijms241914654

Figure 1.

Figure 1

SUN11602 promoted motor recovery, improved spinal cord tissue damage, and downregulated MPO activity after an SCI. From the first day of treatment with SUN11602 at 5 mg/kg, the mice already showed lessened motor deficits compared with the SCI group (A). Histological evaluations indicated the loss of spinal cord morphology in the SCI group (C,C1,G) than in the Sham group (B,B1,G). SUN11602, especially at the dose of 5 mg/kg, restored morphological tissue (F,F1,G), whereas SUN11602 at the doses of 1 mg/kg (D,D1,G) and 2.5 mg/kg were not efficacious (E,E1,G). MPO activity levels were high in the SCI group compared with the control group (H). Only SUN11602 at 5 mg/kg reduced MPO levels (H). Black arrows indicate morphological changes. The results of the histological evaluations are displayed at 20× and 40× magnifications. Data are expressed as mean ± SD where N = 10 mice for each group. One–Way and Two-way ANOVA test. *** p < 0.001 vs. Sham; ## p < 0.01 vs. SCI, ### p < 0.001 vs. SCI; ND: not detectable.